Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
ONL Therapeutics
company
About
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1M
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2011
- Number Of Employee
- 1 - 10
- Operating Status
- Active
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptor cell.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$5.25M
ONL Therapeutics has raised a total of
$5.25M
in funding over 2 rounds. Their latest funding was raised on
May 17, 2017 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 17, 2017 | Series A | $4.25M | 1 | — | — | Detail |
| Mar 21, 2017 | Grant | $1M | 1 |
National Institutes of Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
ONL Therapeutics is funded by 2 investors.
National Institutes of Health
and Hestia Investments
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
